Form 4: Shattuck Labs CMO Granted Stock Options, Sells Shares for Tax

Shattuck Labs' Chief Medical Officer, Arundathy N. Pandite, was granted 487,800 stock options and simultaneously disposed of 6,851 shares of common stock to cover tax obligations.

Summary

• Arundathy N. Pandite, Chief Medical Officer of Shattuck Labs, Inc. (STTK), reported transactions on January 10, 2026.
• Pandite was granted options to purchase 487,800 shares of common stock with an exercise price of $4.75 per share.
• These options will vest over time, with one-quarter vesting on January 10, 2027, and the remainder vesting in equal monthly installments through January 10, 2030. The options expire on January 10, 2036.
• Concurrently, Pandite disposed of 6,851 shares of common stock at a price of $4.75 per share to satisfy tax withholding obligations related to a vesting event.
• Following these transactions, Pandite directly owns 199,414 shares of common stock and 487,800 derivative securities (options).

Sentiment

Score: 7

Explanation: The grant of a substantial number of stock options to a key executive is generally a positive signal, indicating management retention and alignment with long-term company performance. The sale of shares for tax purposes is a neutral event.

Positives

• Chief Medical Officer Arundathy N. Pandite was granted a significant number of stock options (487,800 shares), indicating continued alignment of management's interests with shareholders.
• The grant of options suggests confidence in the company's future performance and a commitment to retaining key executives.

Negatives

• The disposition of 6,851 shares of common stock, even for tax purposes, represents a reduction in direct share ownership.

Future Outlook

The grant of stock options with a vesting schedule extending to January 10, 2030, indicates a long-term incentive structure for the Chief Medical Officer, aligning their future compensation with the company's long-term performance.

Industry Context

This is a routine insider transaction for an executive, common in the biotechnology or pharmaceutical industry where equity compensation is a significant component of executive pay, designed to incentivize long-term performance and retention.

Related Party Transactions

• The grant of stock options to the Chief Medical Officer is a transaction between the company and a key executive, which is a form of related party transaction.

Stakeholder Impact

• Shareholders: The grant of options aligns the Chief Medical Officer's incentives with shareholder value creation over the long term. The tax-related sale is a minor dilution event.
• Employees: This transaction highlights the company's compensation strategy, which includes equity incentives for key personnel.

Next Steps

• The granted stock options will begin vesting on January 10, 2027, with full vesting by January 10, 2030.
• The Chief Medical Officer will continue to hold 199,414 shares of common stock and 487,800 stock options.

Key Dates

Recommendation

The filing reports a routine insider transaction involving an option grant and a tax-related sale. While the option grant is a positive for executive alignment, it doesn't fundamentally change the company's operational or financial outlook to warrant a strong buy or sell recommendation based solely on this Form 4. It's an expected part of executive compensation.

Keywords

Shattuck Labs, STTK, Form 4, Insider Transaction, Stock Options, Chief Medical Officer, Equity Grant, Tax Withholding, Arundathy N. Pandite